BRPI1007350A2 - compostos espiro heterocíclicos bicíclicos - Google Patents
compostos espiro heterocíclicos bicíclicosInfo
- Publication number
- BRPI1007350A2 BRPI1007350A2 BRPI1007350A BRPI1007350A BRPI1007350A2 BR PI1007350 A2 BRPI1007350 A2 BR PI1007350A2 BR PI1007350 A BRPI1007350 A BR PI1007350A BR PI1007350 A BRPI1007350 A BR PI1007350A BR PI1007350 A2 BRPI1007350 A2 BR PI1007350A2
- Authority
- BR
- Brazil
- Prior art keywords
- heterocyclic compounds
- spiro heterocyclic
- bicyclic spiro
- bicyclic
- compounds
- Prior art date
Links
- -1 bicyclic spiro heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14714309P | 2009-01-26 | 2009-01-26 | |
| US61/147,143 | 2009-01-26 | ||
| PCT/IL2010/000064 WO2010084499A2 (en) | 2009-01-26 | 2010-01-26 | Bicyclic heterocyclic spiro compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI1007350A2 true BRPI1007350A2 (pt) | 2018-03-06 |
| BRPI1007350B1 BRPI1007350B1 (pt) | 2020-11-17 |
| BRPI1007350B8 BRPI1007350B8 (pt) | 2021-05-25 |
Family
ID=42291285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1007350A BRPI1007350B8 (pt) | 2009-01-26 | 2010-01-26 | compostos espiro heterocíclicos bicíclicos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8673931B2 (pt) |
| EP (1) | EP2389383B1 (pt) |
| JP (2) | JP5874878B2 (pt) |
| KR (2) | KR20150116466A (pt) |
| CN (1) | CN102361876B (pt) |
| AU (1) | AU2010207486B2 (pt) |
| BR (1) | BRPI1007350B8 (pt) |
| CA (1) | CA2750777C (pt) |
| NZ (1) | NZ594768A (pt) |
| RU (1) | RU2506266C2 (pt) |
| WO (1) | WO2010084499A2 (pt) |
| ZA (1) | ZA201106221B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150116466A (ko) * | 2009-01-26 | 2015-10-15 | 이스라엘 인스티튜트 포 바이올로지컬 리서치 | 이환형 헤테로사이클릭 스피로 화합물 |
| JP5909070B2 (ja) * | 2010-10-28 | 2016-04-26 | 国立大学法人 東京大学 | Ｇｓ共役受容体に対する医薬品候補化合物をスクリーニングする方法 |
| DK2882428T3 (en) | 2012-07-13 | 2019-04-15 | Pain Therapeutics Inc | PROCEDURE TO INHIBIT TAU PHOSPHORIZATION |
| WO2014113893A1 (en) * | 2013-01-28 | 2014-07-31 | University Of Manitoba | Use of galantamine and related compounds for treatment of inflammatory bowel diseases |
| GB201504675D0 (en) * | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| RU2604878C1 (ru) * | 2015-11-17 | 2016-12-20 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | 7-АМИНО-2,2',4-ТРИОКСО-5'-ФЕНИЛ-1,1',2,2',3,4-ГЕКСАГИДРОСПИРО{ПИРАНО[2,3-d]ПИРИМИДИН-5,3'-ПИРРОЛ}-6-КАРБОНИТРИЛЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| EP3768261A1 (en) | 2018-03-22 | 2021-01-27 | NSC THERAPEUTICS GmbH | Compounds and methods for use in the treatment of microglia-mediated disorders |
| AU2020361735B2 (en) | 2019-10-09 | 2024-04-18 | Novartis Ag | 2-azaspiro(3.4)octane derivatives as M4 agonists |
| KR102798432B1 (ko) | 2019-10-09 | 2025-04-22 | 노파르티스 아게 | M4 작용제로서의 5-옥사-2-아자스피로[3.4]옥탄 유도체 |
| WO2021228123A1 (zh) * | 2020-05-12 | 2021-11-18 | 北京广为医药科技有限公司 | 调节nmda受体活性的化合物、其药物组合物及用途 |
| WO2024026480A1 (en) * | 2022-07-29 | 2024-02-01 | Anavex Life Sciences Corp. | Compositions and methods for prevention of cognitive decline caused by degenerative diseases |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3481942A (en) * | 1968-09-06 | 1969-12-02 | Smithkline Corp | Oxa-diazaspiro(4.5)decane compounds |
| JPS60208590A (ja) * | 1984-03-30 | 1985-10-21 | 株式会社日立製作所 | エレベ−タ−敷居装置 |
| EP0189370A3 (de) * | 1985-01-16 | 1988-01-27 | Sandoz Ag | Spiro-dioxolane, -dithiolane und -oxothiolane |
| DE3501225A1 (de) * | 1985-01-16 | 1986-07-24 | Sandoz-Patent-GmbH, 7850 Lörrach | Spirodioxolane, ihre herstellung und verwendung |
| US4855290A (en) * | 1985-05-10 | 1989-08-08 | State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research | Derivatives of quinuclidine |
| US5179079A (en) | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
| JPS63208590A (ja) * | 1987-02-24 | 1988-08-30 | Yamanouchi Pharmaceut Co Ltd | ヘテロ環式スピロ化合物及びその製造法 |
| JPS63208844A (ja) * | 1987-02-26 | 1988-08-30 | Konica Corp | 有機着色物質の光褪色防止方法 |
| US4981858A (en) | 1987-08-13 | 1991-01-01 | State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research | Optical isomers |
| IL87234A (en) * | 1987-08-13 | 1992-02-16 | Israel Inst Biolog Res | Optical isomers of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine,their preparation and pharmaceutical compositions containing them |
| ATE122353T1 (de) * | 1987-10-05 | 1995-05-15 | Yamanouchi Pharma Co Ltd | Heterozyklische spiroverbindungen und ihre herstellung. |
| US4900830A (en) | 1987-10-28 | 1990-02-13 | Israel Institute For Biological Research | Process for labelling sulfur-containing compounds |
| US4876260A (en) | 1987-10-28 | 1989-10-24 | State Of Israel, Israel Institute Of Biological Research | Oxathiolanes |
| IT1223343B (it) | 1987-11-03 | 1990-09-19 | Also Lab Sas | Formulazioni farmaceutiche per somministrazione transdermica |
| GB8808433D0 (en) * | 1988-04-11 | 1988-05-11 | Merck Sharp & Dohme | Therapeutic agents |
| GB8816299D0 (en) * | 1988-07-08 | 1988-08-10 | Merck Sharp & Dohme | Therapeutic agents |
| US5053412A (en) | 1990-04-10 | 1991-10-01 | Israel Institute For Biological Research | Spiro nitrogen-bridged heterocyclic compounds |
| JPH02164882A (ja) | 1988-12-20 | 1990-06-25 | Yamanouchi Pharmaceut Co Ltd | スピロ化合物及びその中間体 |
| US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| AU5194990A (en) | 1989-02-23 | 1990-09-26 | Rorer International (Holdings), Inc. | Therapeutic aerosol formulations |
| US5075317A (en) * | 1989-06-21 | 1991-12-24 | Fisons Corporation | Spirofurane derivatives |
| GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
| US5221675A (en) * | 1989-12-15 | 1993-06-22 | Abbott Laboratories | Aza-spirocyclic compounds that enhance cholinergic neurotransmission |
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| IL97726A (en) * | 1990-04-10 | 1994-12-29 | Israel Inst Biolog Res | Pharmaceutical compositions containing compounds with bridged and unbridged heterocyclic groups, spiro-connected with oxazoline and thiazoline groups, and some new such compounds |
| US5534520A (en) * | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
| US5407938A (en) * | 1990-04-10 | 1995-04-18 | Israel Institute For Biological Research | Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines) |
| US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
| US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
| US5403931A (en) * | 1991-05-15 | 1995-04-04 | Yamanouchi Pharmaceutical Co., Ltd. | (-)-(S)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4.5]decane L-tartrate |
| US6632456B1 (en) | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
| US5707641A (en) | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US5635161A (en) | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
| US6120794A (en) | 1995-09-26 | 2000-09-19 | University Of Pittsburgh | Emulsion and micellar formulations for the delivery of biologically active substances to cells |
| EP0801557B1 (en) | 1995-10-12 | 2003-07-02 | Supergen, Inc. | Liposome formulations of 5beta steroids |
| DE19637043A1 (de) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien |
| BR9911031A (pt) | 1998-05-20 | 2002-01-29 | Liposome Co Inc | Novas formulações em partìculas |
| US6451349B1 (en) | 1998-08-19 | 2002-09-17 | Quadrant Healthcare (Uk) Limited | Spray-drying process for the preparation of microparticles |
| GB9814172D0 (en) | 1998-06-30 | 1998-08-26 | Andaris Ltd | Formulation for inhalation |
| AUPP494798A0 (en) | 1998-07-29 | 1998-08-20 | Pacific Biolink Pty Limited | Protective protein formulation |
| US6290987B1 (en) | 1998-09-27 | 2001-09-18 | Generex Pharmaceuticals, Inc. | Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids |
| WO2000023444A1 (en) * | 1998-10-21 | 2000-04-27 | Abbott Laboratories | 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
| US6294153B1 (en) | 1998-12-21 | 2001-09-25 | Generex Pharmaceuticals, Inc. | Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
| EP1338272A1 (en) | 1998-12-21 | 2003-08-27 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate |
| US6436367B1 (en) | 1998-12-21 | 2002-08-20 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application |
| BR0007974A (pt) | 1999-02-03 | 2001-10-30 | Powderject Res Ltd | Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo |
| EP1158961A1 (en) | 1999-03-08 | 2001-12-05 | PowderJect Research Limited | Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds |
| AU3957400A (en) | 1999-04-16 | 2000-11-02 | Novo Nordisk A/S | Dry, mouldable drug formulation |
| JP2003501404A (ja) | 1999-06-04 | 2003-01-14 | デルルックス ファーマシューティカル コーポレイション | 薬剤の脱水粒子からなる製剤およびこれの調製方法 |
| US20010036481A1 (en) | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| CA2382821A1 (en) | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| MXPA02007052A (es) | 2000-01-20 | 2002-12-13 | Basilea Pharmaceutica Ag | Composiciones que se administran nasalmente y que contienen peptidos ciclicos. |
| EP1129705A1 (en) | 2000-02-17 | 2001-09-05 | Rijksuniversiteit te Groningen | Powder formulation for inhalation |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0009468D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
| CA2406206C (en) | 2000-04-17 | 2012-03-20 | Vectura Limited | Improvements in or relating to formulations for use in inhaler devices |
| AU2001290678A1 (en) | 2000-09-08 | 2002-03-22 | Powderject Research Limited | Alginate particle formulation |
| FI20002768L (fi) | 2000-12-18 | 2002-06-19 | Licentia Oy | Enteropäällysteisiä lääkekoostumuksia ja niiden valmistus |
| GB0107106D0 (en) | 2001-03-21 | 2001-05-09 | Boehringer Ingelheim Pharma | Powder inhaler formulations |
| DE10130020A1 (de) * | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
| US20030019437A1 (en) | 2001-07-26 | 2003-01-30 | John Fore | Ungulate game animal feed system and method |
| ES2307779T3 (es) | 2001-08-16 | 2008-12-01 | Baxter International Inc. | Formulaciones de microparticulas a base de propelentes. |
| WO2003072080A1 (en) | 2002-02-22 | 2003-09-04 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
| AU2003230689B2 (en) | 2002-03-20 | 2006-06-29 | Alkermes, Inc. | Inhalable sustained therapeutic formulations |
| MXPA04010921A (es) * | 2002-05-03 | 2005-05-27 | Israel Inst Biolog Res | Metodos y composiciones para el tratamietno de trastornos del sistema nervioso central y periferico y compuestos novedosos utiles para los mismos. |
| CA2484724C (en) | 2002-05-07 | 2007-01-16 | Ferring B.V. | Pharmaceutical formulations |
| DE10323244A1 (de) | 2003-05-22 | 2004-12-16 | Infineon Technologies Ag | Integrierte Speicher-Schaltungsanordnung, insbesondere UCP-Flash-Speicher |
| DE102005030051A1 (de) * | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| JP2010155827A (ja) * | 2008-12-04 | 2010-07-15 | Takeda Chem Ind Ltd | スピロ環化合物 |
| KR20150116466A (ko) * | 2009-01-26 | 2015-10-15 | 이스라엘 인스티튜트 포 바이올로지컬 리서치 | 이환형 헤테로사이클릭 스피로 화합물 |
-
2010
- 2010-01-26 KR KR1020157026733A patent/KR20150116466A/ko not_active Ceased
- 2010-01-26 NZ NZ594768A patent/NZ594768A/xx unknown
- 2010-01-26 AU AU2010207486A patent/AU2010207486B2/en active Active
- 2010-01-26 RU RU2011134290/04A patent/RU2506266C2/ru active
- 2010-01-26 WO PCT/IL2010/000064 patent/WO2010084499A2/en not_active Ceased
- 2010-01-26 CA CA2750777A patent/CA2750777C/en active Active
- 2010-01-26 EP EP10708648.0A patent/EP2389383B1/en active Active
- 2010-01-26 JP JP2011547054A patent/JP5874878B2/ja active Active
- 2010-01-26 CN CN201080013672.6A patent/CN102361876B/zh active Active
- 2010-01-26 KR KR1020117019687A patent/KR101675174B1/ko active Active
- 2010-01-26 BR BRPI1007350A patent/BRPI1007350B8/pt active IP Right Grant
- 2010-01-26 US US13/146,209 patent/US8673931B2/en active Active
-
2011
- 2011-08-24 ZA ZA2011/06221A patent/ZA201106221B/en unknown
-
2015
- 2015-07-10 JP JP2015139266A patent/JP2015172098A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP5874878B2 (ja) | 2016-03-02 |
| BRPI1007350B8 (pt) | 2021-05-25 |
| KR20110127160A (ko) | 2011-11-24 |
| WO2010084499A2 (en) | 2010-07-29 |
| NZ594768A (en) | 2013-02-22 |
| JP2015172098A (ja) | 2015-10-01 |
| CA2750777C (en) | 2018-04-03 |
| ZA201106221B (en) | 2013-04-24 |
| US20110281903A1 (en) | 2011-11-17 |
| US8673931B2 (en) | 2014-03-18 |
| AU2010207486A1 (en) | 2011-09-15 |
| KR101675174B1 (ko) | 2016-11-10 |
| WO2010084499A3 (en) | 2010-10-21 |
| AU2010207486B2 (en) | 2013-03-07 |
| RU2011134290A (ru) | 2013-03-10 |
| JP2012515763A (ja) | 2012-07-12 |
| EP2389383A2 (en) | 2011-11-30 |
| BRPI1007350B1 (pt) | 2020-11-17 |
| RU2506266C2 (ru) | 2014-02-10 |
| WO2010084499A9 (en) | 2010-12-09 |
| CA2750777A1 (en) | 2010-07-29 |
| CN102361876B (zh) | 2015-02-04 |
| KR20150116466A (ko) | 2015-10-15 |
| CN102361876A (zh) | 2012-02-22 |
| EP2389383B1 (en) | 2019-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2020505I1 (lt) | Nauji tricikliniai junginiai | |
| EP2391627A4 (en) | BICYCLIC PYRAZOLO HETEROCYCLES | |
| DE602008003015D1 (de) | Heterocyclische spiroverbindungen | |
| BRPI1007350A2 (pt) | compostos espiro heterocíclicos bicíclicos | |
| LTC2441753I2 (lt) | Tetraciklinis junginys | |
| IL213690A0 (en) | Novel bicyclic heterocyclic compound | |
| BR112012005616A2 (pt) | compostos antivirais heterocíclicos | |
| BRPI1016189A2 (pt) | compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2 | |
| BRPI1013614A2 (pt) | compostos substituídos de espiro-amida | |
| BRPI1010852A2 (pt) | compostos antivirais heterocíclicos | |
| DK2376490T3 (da) | Imidazopyridinforbindelser | |
| BR112012008061A2 (pt) | compostos de oxima heterocíclica | |
| BRPI1005525A2 (pt) | compostos de azaazuleno | |
| BRPI1016266A2 (pt) | compostos antivirais heterocíclicos | |
| PT2569314T (pt) | Inibidores bicíclicos de cinase fundidos | |
| SMT201600031B (it) | Composti eterociclici di fenossimetile | |
| BR112013010643A2 (pt) | compostos heterocíclicos | |
| BRPI1016207A2 (pt) | compostos de 4-azetidinil-1-heteroaril-ciclohexano antagonistas de ccr2 | |
| BRPI0821142A2 (pt) | derivados heterocíclicos bicíclicos | |
| ZA201403513B (en) | Bicyclic heterocyclic compound | |
| BRPI1010900A2 (pt) | compostos antivirais heterocíclicos | |
| BR112012009784A2 (pt) | composto benzazepínico | |
| BRPI1009199A2 (pt) | compostos de pirazinoisoquinolina | |
| BRPI1014080A2 (pt) | Compostos substituidos de enaminocarbolina | |
| IL214295A0 (en) | Bicyclic heterocyclic spiro compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |